PE20221421A1 - METODO PARA EL TRATAMIENTO DE CANCER UTILIZANDO CELULA ADYUVANTE ARTIFICIAL (aAVC) - Google Patents
METODO PARA EL TRATAMIENTO DE CANCER UTILIZANDO CELULA ADYUVANTE ARTIFICIAL (aAVC)Info
- Publication number
- PE20221421A1 PE20221421A1 PE2022000981A PE2022000981A PE20221421A1 PE 20221421 A1 PE20221421 A1 PE 20221421A1 PE 2022000981 A PE2022000981 A PE 2022000981A PE 2022000981 A PE2022000981 A PE 2022000981A PE 20221421 A1 PE20221421 A1 PE 20221421A1
- Authority
- PE
- Peru
- Prior art keywords
- aavc
- cancer
- treatment
- alpha
- prevention
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000002671 adjuvant Substances 0.000 title 1
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- User Interface Of Digital Computer (AREA)
Abstract
La presente invencion encuentra escala apropiadas de la dosis de alfa-GalCer cargado en la superficie de la celula aAVC, asi como la cantidad de alfa-GalCer cargado en la superficie de la celula aAVC, en una composicion farmaceutica que contiene aAVC, las cuales se prefieren en terminos de garantizar la efectividad y seguridad en el tratamiento y prevencion de un cancer utilizando aAVC; y proporciona un metodo efectivo y seguro para el tratamiento o prevencion de un cancer utilizando aAVC para el tratamiento efectivo y seguro de un cancer; y una composicion farmaceutica que comprende a la misma, etc.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019217712 | 2019-12-02 | ||
| PCT/JP2020/044587 WO2021112056A1 (ja) | 2019-12-02 | 2020-12-01 | 人工アジュバント細胞（ａＡＶＣ）を用いたがんの治療方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221421A1 true PE20221421A1 (es) | 2022-09-20 |
Family
ID=76222356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000981A PE20221421A1 (es) | 2019-12-02 | 2020-12-01 | METODO PARA EL TRATAMIENTO DE CANCER UTILIZANDO CELULA ADYUVANTE ARTIFICIAL (aAVC) |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11617790B2 (es) |
| EP (1) | EP4070810A4 (es) |
| JP (2) | JP6912765B1 (es) |
| KR (1) | KR20220119029A (es) |
| CN (1) | CN114929272A (es) |
| AR (1) | AR122341A1 (es) |
| AU (1) | AU2020398783A1 (es) |
| BR (1) | BR112022010750A2 (es) |
| CA (1) | CA3162121A1 (es) |
| CL (1) | CL2022001458A1 (es) |
| CO (1) | CO2022008737A2 (es) |
| CR (1) | CR20220319A (es) |
| DO (1) | DOP2022000109A (es) |
| EC (1) | ECSP22049665A (es) |
| IL (1) | IL293483A (es) |
| JO (1) | JOP20220122A1 (es) |
| MX (1) | MX2022006712A (es) |
| PE (1) | PE20221421A1 (es) |
| TW (1) | TW202134265A (es) |
| WO (1) | WO2021112056A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2441468B1 (en) * | 2006-02-22 | 2020-01-08 | Riken | Immunotherapy by using cell capable of co-expressing target antigen and cd1d and pulsed with cd1d ligand |
| US20130189302A1 (en) * | 2006-02-22 | 2013-07-25 | Riken | Immunotherapeutic method using artificial adjuvant vector cells that co-express cd1d and target antigen |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2441468B1 (en) | 2006-02-22 | 2020-01-08 | Riken | Immunotherapy by using cell capable of co-expressing target antigen and cd1d and pulsed with cd1d ligand |
| US20130189302A1 (en) * | 2006-02-22 | 2013-07-25 | Riken | Immunotherapeutic method using artificial adjuvant vector cells that co-express cd1d and target antigen |
| JP2007261876A (ja) | 2006-03-28 | 2007-10-11 | Tdk Corp | 誘電体粒子、誘電体磁器組成物およびその製造方法 |
| JPWO2010061930A1 (ja) | 2008-11-28 | 2012-04-26 | 独立行政法人理化学研究所 | ＣＤ１ｄ及び標的抗原の共発現アロ細胞を用いた免疫療法 |
| KR101194265B1 (ko) | 2008-12-01 | 2012-10-29 | 주식회사 한국인삼공사 | 해양심층수를 이용하여 인삼 또는 홍삼 농축액의 고미 제거방법 |
| BR112012024375A2 (pt) | 2010-03-25 | 2016-05-24 | 3M Innovative Properties Co | camada compósita |
| US10316332B2 (en) * | 2011-07-29 | 2019-06-11 | Riken | Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product |
| JPWO2013018778A1 (ja) | 2011-07-29 | 2015-03-05 | 独立行政法人理化学研究所 | ウィルムス腫瘍遺伝子産物またはその断片をコードしている改変型核酸構築物を含んでいる免疫治療用細胞、当該細胞の製造方法、および当該核酸構築物 |
-
2020
- 2020-12-01 WO PCT/JP2020/044587 patent/WO2021112056A1/ja active Application Filing
- 2020-12-01 CN CN202080083505.2A patent/CN114929272A/zh active Pending
- 2020-12-01 TW TW109142273A patent/TW202134265A/zh unknown
- 2020-12-01 JO JOP/2022/0122A patent/JOP20220122A1/ar unknown
- 2020-12-01 AU AU2020398783A patent/AU2020398783A1/en active Pending
- 2020-12-01 PE PE2022000981A patent/PE20221421A1/es unknown
- 2020-12-01 KR KR1020227020631A patent/KR20220119029A/ko active Search and Examination
- 2020-12-01 BR BR112022010750A patent/BR112022010750A2/pt unknown
- 2020-12-01 CR CR20220319A patent/CR20220319A/es unknown
- 2020-12-01 US US17/312,363 patent/US11617790B2/en active Active
- 2020-12-01 EP EP20897410.5A patent/EP4070810A4/en active Pending
- 2020-12-01 IL IL293483A patent/IL293483A/en unknown
- 2020-12-01 MX MX2022006712A patent/MX2022006712A/es unknown
- 2020-12-01 AR ARP200103336A patent/AR122341A1/es unknown
- 2020-12-01 JP JP2021513476A patent/JP6912765B1/ja active Active
- 2020-12-01 CA CA3162121A patent/CA3162121A1/en active Pending
-
2021
- 2021-06-29 JP JP2021108075A patent/JP2021155443A/ja active Pending
-
2022
- 2022-05-24 DO DO2022000109A patent/DOP2022000109A/es unknown
- 2022-06-02 CL CL2022001458A patent/CL2022001458A1/es unknown
- 2022-06-23 CO CONC2022/0008737A patent/CO2022008737A2/es unknown
- 2022-06-24 EC ECSENADI202249665A patent/ECSP22049665A/es unknown
-
2023
- 2023-03-06 US US18/179,289 patent/US20230381305A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220016239A1 (en) | 2022-01-20 |
| TW202134265A (zh) | 2021-09-16 |
| US11617790B2 (en) | 2023-04-04 |
| JPWO2021112056A1 (ja) | 2021-12-02 |
| CA3162121A1 (en) | 2021-06-10 |
| BR112022010750A2 (pt) | 2022-08-16 |
| WO2021112056A1 (ja) | 2021-06-10 |
| AR122341A1 (es) | 2022-09-07 |
| JP6912765B1 (ja) | 2021-08-04 |
| AU2020398783A1 (en) | 2022-06-09 |
| DOP2022000109A (es) | 2022-10-16 |
| CN114929272A (zh) | 2022-08-19 |
| IL293483A (en) | 2022-08-01 |
| CO2022008737A2 (es) | 2022-08-09 |
| US20230381305A1 (en) | 2023-11-30 |
| KR20220119029A (ko) | 2022-08-26 |
| MX2022006712A (es) | 2022-09-12 |
| EP4070810A4 (en) | 2024-04-17 |
| CR20220319A (es) | 2022-11-03 |
| CL2022001458A1 (es) | 2023-02-24 |
| JP2021155443A (ja) | 2021-10-07 |
| JOP20220122A1 (ar) | 2023-01-30 |
| EP4070810A1 (en) | 2022-10-12 |
| ECSP22049665A (es) | 2022-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201700192A (es) | Combinaciones de compuestos activos desde el punto de vista fungicida | |
| AR105712A1 (es) | Composiciones de insulina de rápida acción | |
| DOP2017000271A (es) | Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t | |
| DOP2022000109A (es) | MÉTODO PARA EL TRATAMIENTO DE CÁNCER UTILIZANDO CÉLULA ADYU-VANTE ARTIFICIAL (aAVC) | |
| MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
| ECSP17077930A (es) | Métodos y kits para tratar la depresión | |
| UY38160A (es) | Partículas implantables y métodos relacionados | |
| EA201692285A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| CO2020013600A2 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| BR112018008601A2 (pt) | composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer | |
| CL2022000194A1 (es) | Uso para tratar la enfermedad de hemorragia alveolar difusa asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384) | |
| AR056801A1 (es) | Terapia combinada anti- proliferativa con determinados agentes quimioterapeuticos basados en platino e inhibidores de egfr o analogos de pirimidina | |
| UY31818A (es) | Método para proteger soja frente a la infección por hongos | |
| CO2017006983A2 (es) | Una composición fungicida que comprende una n-ciclopropil- n-[bencilo sustituido]-3-(difluorometil)-5-fluoro-1- metil-1-h-pirazol-4-carboxamida o derivado de tiocarboxamida y dos compuestos fungicidas activos adicionales | |
| CL2020002993A1 (es) | Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica (divisional de solicitud no 1304-2019) | |
| BR112018003836A2 (pt) | combinações de inibidor de btk para tratar mieloma múltiplo | |
| UY37306A (es) | Combinaciones de compuestos activos | |
| MX2021001612A (es) | Compuestos utiles en terapia del vih. | |
| WO2019018451A3 (en) | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED PROXIMITY EFFECTS CAUSED BY RADIATION OR RADIATION THERAPY | |
| CO2023008271A2 (es) | Compuesto de heteroarilcarboxamida | |
| BR112018014723A2 (pt) | fantasmas bacterianos para o tratamento de câncer | |
| CL2021001096A1 (es) | Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196) | |
| MX2019010931A (es) | Metodos, composiciones, y kits para tratar y/o prevenir un efecto secundario asociado con radiacion y/o exposicion a quimioterapia. | |
| CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
| PE20220250A1 (es) | Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma |